Grifols (NASDAQ:GRFS) Shares Gap Down – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares gapped down prior to trading on Monday . The stock had previously closed at $8.73, but opened at $8.39. Grifols shares last traded at $8.49, with a volume of 91,998 shares trading hands.

Grifols Stock Down 2.7 %

The business has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $7.74. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. Equities analysts expect that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Grifols

Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares in the last quarter. Signaturefd LLC boosted its stake in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares in the last quarter. Cohen Investment Advisors LLC bought a new position in Grifols during the first quarter valued at about $80,000. AQR Capital Management LLC acquired a new position in Grifols during the second quarter worth about $89,000. Finally, Cetera Advisors LLC acquired a new stake in Grifols in the 1st quarter valued at about $147,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.